The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on cutaneous manifestations of rheumatic diseases, gout, macrophage activation syndrome and vasculitis.
The FDA as approved the biosimilar treatments denosumab-nxxp (Bildyos) and denosumab-nxxp (Bilprevda) for all indications of denosumab, their reference product, including osteoporosis in postmenopausal women.
The ACR honors excellence in rheumatology. Meet the 2025 Awards of Distinction recipients, ACR Masters & Distinguished Fellows recognized at ACR Convergence 2025.
A recent Proceedings of the National Academy of Sciences study found that high-intensity aerobic exercise may reduce the release of cell-free DNA & tamp down inflammation over time.
A recent Arthritis & Rheumatology review article explores the immune system’s mechanism for creating B cells that respond to diverse pathogens while preserving immune tolerance & highlights key insights for rheumatologists.
In a powerful op-ed published by Fierce Healthcare, rheumatologists Amanda Myers, MD, and Rebecca Shepherd, MD, MBA—both volunteer advocates with the ACR—highlighted the critical role of the Centers for Medicare & Medicaid Services (CMS) in improving access to life-changing medications for patients with autoimmune and rheumatic diseases. Many patients with chronic conditions, such as rheumatoid…